FDA advisers back approval of Bayer's PAH drug riociguat

An FDA advisory panel recommended the approval of Bayer's riociguat as a treatment for two types of pulmonary arterial hypertension. The agency is expected to issue its decision in October. If approved, the drug would be marketed as Adempas.

View Full Article in:

Reuters · Wall Street Journal (tiered subscription model), The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC